TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10992828
Drug: Intravenous ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen 1 mg kg‐1
Study: 10992828
Drug: Oral ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoprofen 1 mg kg‐1
Study: 10992828
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and i.v. placebo
Study: 31399460
Drug: Daily observed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily observed treatment
Study: 31399460
Drug: Treatment dispensed
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment dispensed every 2 weeks
Study: 31399460
Drug: Treatment dispensed
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment dispensed every 2 weeks with adherence psychological intervention
Study: 24418726
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg intravenously, acute)
Study: 24418726
Drug: Acetazolamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (2 g orally, prolonged)
Study: 24418726
Drug: Inhaled CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled CO2 (1%-2%) during exercise
Study: 22851561
Drug: Standard (conventional)
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard (conventional) fractionated radiotherapy (STRT) followed by chemotherapy
Study: 22851561
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (HFRT) followed by chemotherapy
Study: 22851561
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (HFRT and STRT)
Study: 19220307
Drug: Sumatriptan/Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan/Naproxen Sodium 85/500 mg (S/NS)
Study: 15683159
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and hepatitis B vaccine
Study: 15683159
Drug: Monovalent hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent hepatitis A and hepatitis B vaccine
Study: 2126437
Drug: Pravastatin 5
Normalized name: pravastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 5 mg
Study: 8726243
Drug: Pravastatin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (all doses)
Study: 7211425
Drug: Pimozide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (1 to 2.6 mg per day)
Study: 23893418
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution) injection
Study: 19552748
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg three times daily for 6 days)
Study: 16735920
Drug: Hypertonic Dead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic Dead Sea salt (DSS) solution
Study: 11370224
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (PPI + three antibiotics)
Study: 11370224
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (PPI + two antibiotics)
Study: 3801953
Drug: Combination antiemetic
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiemetic therapy
Study: 25046948
Drug: Wuling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling Capsule (WC), 0.33 g each pill, 3 pills per day, three times per day
Study: 25046948
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 pills per day, three times per day
Study: 19912735
Drug: Wuling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling Capsule (WC)
Study: 17880761
Drug: IL-15 treatment
Normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-15 treatment in vitro
Study: 11837554
Drug: BMS‐284756 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐284756 (400 mg) after a high-fat meal
Study: 11837554
Drug: BMS‐284756 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐284756 (400 mg) in a fasted state
Study: 7587260
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of preoperative, intraoperative, and postoperative variables (including Parsonnet score, APACHE II and III scores)
Study: 1775733
Drug: Pizotifen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen 0.5 mg
Study: 1775733
Drug: Metergoline 6
Normalized name: Metergoline
DrugBank: Metergoline (DB13520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline 6 mg
Study: 760752
Drug: Methysergide 2
Normalized name: methysergide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methysergide 2 mg
Study: 6133757
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg LH-RH daily for 4 weeks (placebo-controlled)
Study: 6133757
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg LH-RH daily for 4 weeks (open study)
Study: 28233071
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser group (ALG) received pulsed high-intensity laser therapy (HILT) three times per week for 6 weeks, along with 10 mg cetirizine tablets twice daily and 10 mg at bedtime.
Study: 17577323
Drug: Lactobacillus brevis-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus brevis-containing lozenges
Study: 15631350
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (n = 31)
Study: 15631350
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (n = 33)
Study: 11294772
Drug: Ghrelin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (10 microg/kg, intravenous bolus)
Study: 7760586
Drug: Flunarizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (5 mg twice-daily for 1 month, then 5 mg once-daily for 2 months)
Study: 7760586
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching capsule)
Study: 23669294
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg intravenous infusion per year)
Study: 16406221
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (starting from 2 mIU/min, increased every 30 min up to 40 mIU/min)
Study: 12553389
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine 8 mg kg(‐1)
Study: 12553389
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine 4 mg kg(‐1)
Study: 12553389
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine 6 mg kg(‐1)
Study: 1739573
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium suppositories 150‐200 mg day‐1
Study: 24740822
Drug: Intraarticular sprifermin
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular sprifermin (10 μg, 30 μg, 100 μg)
Study: 20586935
Drug: sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential therapy of lamivudine‐interferon‐alpha2b
Study: 9672727
Drug: Modified Cognitive-Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Cognitive-Behavioural Therapy (MCBT)
Study: 9672727
Drug: Conjoint Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint Family Therapy (FT)
Study: 9672727
Drug: Eclectic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eclectic Therapy (ET)
Study: 8608658
Drug: No ACE
Normalized name: Amino Acetic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACE inhibitor
Study: 27825957
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml water
Study: 23564595
Drug: 74 g
Normalized name: WATER 99.9974 g in 100 L ORAL LIQUID [37.4]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 74 g Corinthian raisins
Study: 23564595
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose (reference food)
Study: 21775755
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (ALA) 600 mg once daily
Study: 19857148
Drug: Mould-active agent
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mould-active agent for high-risk allogeneic HSCT recipients
Study: 17030231
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microg) with fluticasone propionate (100 microg) administered twice daily for 12 weeks
Study: 17030231
Drug: Montelukast administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast administered daily for 12 weeks
Study: 6354929
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg t.i.d.
Study: 10828632
Drug: Petrolatum-based formulation
Normalized name: PETROLATUM BASE
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum-based formulation delivered via a novel diaper
Study: 10828633
Drug: Control diaper
Normalized name: Vanicream Diaper Rash
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control diaper (identical to test product without petrolatum formulation)
Study: 2876485
Drug: Clonazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (1 mg h.s.)
Study: 2876485
Drug: Temazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (30 mg h.s.)
Study: 31828166
Drug: Adjusted insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjusted insulin (daily insulin needed on the day after hemodialysis)
Study: 31828166
Drug: Nonadjusted insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonadjusted insulin (25% decrease in daily insulin needed on the day after hemodialysis)
Study: 26437376
Drug: ITX5061 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITX5061 (150 mg immediately before and after transplant and daily for 1 week)
Study: 26437376
Drug: Control (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (first 13 patients did not receive drug)
Study: 19488642
Drug: Combination hydralazine/nitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination hydralazine/nitrate
Study: 17250745
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of physostigmine
Study: 15774291
Drug: Glutamine granules
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine granules (0.5 g/kg per day for 14 days)
Study: 12081987
Drug: Omapatrilat 80
Normalized name: OMAPATRILAT
DrugBank: Omapatrilat (DB00886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 80 mg daily
Study: 14517164
Drug: Enalapril 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 40 mg daily
Study: 7656295
Drug: Brushing twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing twice a day
Study: 2697708
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic therapy (group 4, n = 32)
Study: 180196
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with 3% adenine arabinoside
Study: 180196
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with placebo ointment
Study: 31691472
Drug: MYL-1501D (weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYL-1501D (weeks 0-12), reference insulin glargine (weeks 12-24), MYL-1501D (weeks 24-36)
Study: 31691472
Drug: Reference insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference insulin glargine for 36 weeks
Study: 31691472
Drug: MYL-1501D and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYL-1501D and reference insulin glargine
Study: 30084719
Drug: Maternal ADHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal ADHD treatment (group psychotherapy and open methylphenidate medication)
Study: 30084719
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (individual counselling without psycho‐ or pharmacotherapy)
Study: 14872173
Drug: F3212 (dengue
Approvals — FDA: no, EMA: no, PMDA: no
Description: F3212 (dengue vaccine containing 3, 2, 1 and 2 log10 of the 50% cell culture infective dose of serotypes 1, 2, 3 and 4)
Study: 14872173
Drug: F3313 (dengue
Approvals — FDA: no, EMA: no, PMDA: no
Description: F3313 (dengue vaccine containing 3, 3, 1 and 3 log10 of the 50% cell culture infective dose of serotypes 1, 2, 3 and 4)
Study: 14872173
Drug: Purified Vero
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Vero cell rabies vaccine (control group)
Study: 3294714
Drug: Emepronium bromide
Normalized name: emepronium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emepronium bromide (Cetiprin) 25 mg t.i.d. administered intramuscularly
Study: 11759177
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intramuscularly
Study: 29028848
Drug: Synthetic resorbable
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic resorbable membrane (PLA membrane); test group, 30 implants
Study: 29028848
Drug: Collagen resorbable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen resorbable membrane; control group, 30 implants
Study: 28237253
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of plasma rich in growth factors (PRGF)
Study: 23715891
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 15 mg/kg body weight intravenously before skin incision
Study: 23715891
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% Sodium chloride solution) intravenously before skin incision
Study: 20832243
Drug: Topical honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical honey
Study: 18594749
Drug: Thermal water
Normalized name: thermal water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal water nasal spray 4 times/day for 4 weeks
Study: 18594749
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal spray 4 times/day for 4 weeks
Study: 18594749
Drug: Thermal water
Normalized name: thermal water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal water nasal spray
Study: 18594749
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal spray
Study: 1990896
Drug: Low-dose clonidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose clonidine (7-cm2 transdermal patch + oral 3 micrograms.kg-1)
Study: 1990896
Drug: High-dose clonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clonidine (10.5-cm2 transdermal patch + oral 4.5 micrograms.kg-1 at bedtime and 6.0 micrograms.kg-1 on morning of surgery)
Study: 1990896
Drug: Placebo (occlusive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (occlusive patch without active ingredient + oral placebo tablets)
Study: 6129979
Drug: UK‐33,274 (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK‐33,274 (average dose 4.5 mg)
Study: 6129979
Drug: Prazosin (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (average dose 2.4 mg)
Study: 28624988
Drug: Oral mifepristone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mifepristone (400 mg)
Study: 28624988
Drug: Balloon catheter
Normalized name: Paclitaxel coated angioplasty balloon catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon catheter (Foley's catheter 16 Fr; bulb filled with 30 ml normal saline)
Study: 17683402
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg.kg(-1)
Study: 16361558
Drug: Primary systemic
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary systemic therapy (arm C)
Study: 15997936
Drug: EDTA-T gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA-T gel (5%, 10%, 15%, 20%, 24%) applied for 1, 2, or 3 minutes using passive and active methods
Study: 29160391
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (saline solution)
Study: 10440417
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg loading dose of clopidogrel on day 1, followed by 75 mg daily from day 2 to day 10.
Study: 10440417
Drug: Loading doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading doses of 75 mg, 150 mg, 225 mg, or 300 mg of clopidogrel on day 1, followed by 75 mg daily from day 2 to day 5.
Study: 6640241
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg i.v.
Study: 6640241
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg i.v. + Cefuroxime 1.5 g i.v.
Study: 30883781
Drug: Silver fluoride
Normalized name: SILVER FLUORIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver fluoride (AgF) treatment
Study: 20733558
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with ologen implant
Study: 18052557
Drug: Vitamin B(6)
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B(6) (daily dose of 1200 mg)
Study: 15722001
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) intervention from trained nurses in the community
Study: 15722001
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) intervention
Study: 12131685
Drug: Selective bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective bowel decontamination (SBD) regimen consisting of gentamicin 80 mg + polymyxin E 100 mg + nystatin 2 million units
Study: 30616014
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of oral antibiotics (colistin sulphate 2 × 106 IU 4×/day; neomycin sulphate 500 mg 4×/day) followed by frozen faecal microbiota transplantation (FMT) from unrelated healthy donors
Study: 30513812
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D tablets (1000 IU/day)
Study: 30513812
Drug: Vitamin D-fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-fortified milk (40 IU/200 mL)
Study: 24903663
Drug: Maternal RSV
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal RSV antibody titers in the third trimester and at birth
Study: 24903663
Drug: Higher cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher cord blood RSV antibody titers
Study: 24903663
Drug: Maternal antibody
Normalized name: Maternal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antibody half-life
Study: 24903663
Drug: Ratio of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ratio of infant cord blood to maternal serum RSV antibody titers
Study: 17534541
Drug: Sitz bath
Normalized name: SITZ BATH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitz bath (twice daily) along with analgesics and fiber supplement
Study: 17534541
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (analgesics and fiber supplement only)
Study: 8306409
Drug: OK-432 i.p.
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 i.p. for 7 days, intradermal injection for 1 year at 2-week intervals
Study: 3394332
Drug: Deverol drgs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deverol drgs. (50 mg)
Study: 3394332
Drug: Osiren drgs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osiren drgs. (100 mg)
Study: 29888570
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus intra-articular injection of sodium hyaluronate (2 mL once a week for 5 weeks)
Study: 29888570
Drug: Simple medication
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple medication (intra-articular injection of sodium hyaluronate 2 mL once a week for 5 weeks)
Study: 29083275
Drug: OADs and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OADs and insulin
Study: 23244028
Drug: Telephone-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive-behavioral therapy (T-CBT)
Study: 21564387
Drug: Phenobarbital monotherapy
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital monotherapy
Study: 21564387
Drug: No anti-epileptic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-epileptic therapy
Study: 18089849
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (5 g/m(2) over 24 hours)
Study: 18089849
Drug: Intermediate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose methotrexate (1 g/m(2) over 36 hours)
Study: 16687201
Drug: Single IUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IUI performed 36 h after HCG administration combined with timed intercourse
Study: 16687201
Drug: IUI alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IUI alone performed 36 h after HCG administration